Effects of Intraurethral Injection of Anaesthetic Gel for Transurethral Instrumentation (PDF)
In current clinical practice, 2% lignocaine gel is widely used as a local anaesthetic lubricant before various forms of transurethral instrumentation (urethral catheterization, flexible or rigid cystoscopy, urethral dilatation) [1,2].

BJUI Mini Reviews 2006 June

Lymphadenectomy For Invasive Bladder Cancer: I. Historical Perspective And Contemporary Rationale (PDF)
In the USA bladder cancer is the fourth most common cancer in men and the eighth most common in women, with TCC comprising nearly 90% of all primary bladder tumours.

BJUI Mini Reviews 2006 February

Lymphadenectomy For Invasive Bladder Cancer. II. Technical Aspects And Prognostic Factors (PDF)
The role of a lymphadenectomy in genitourinary tumours has gained recent attention.

BJUI Mini Reviews 2006 February

Structural Characterization Of Myofibroblasts In The Bladder (PDF)
The cellular physiology of the lower urinary tract is in an exciting phase thanks to the identification of a novel cell type, present in the bladder within the detrusor and in the suburothelial space.

BJUI Mini Reviews 2006 January

Bladder Cancer Support Groups And Community Outreach
According to the National Cancer Institute, the prevalence of bladder cancer in the U.S. has surpassed that of lung cancer. This cancer is linked to smoking and occupational exposure to chemicals, yet if detected early, this cancer is very treatable.

Originally Shared at the Oct. 2005 SUNA Annual Meeting

Intravesical Gemcitabine For Superficial Bladder Cancer: Rationale For A New Treatment Option (PDF)
Superficial bladder cancer (SBC) represents nearly 70% of all bladder cancers at first presentation and comprises a heterogeneous population of tumours that do not invade the muscularis propria.

BJUI Mini Reviews 2005 November

The Role Of Repeat Transurethral Resection In The Management Of High-Risk Superficial Transitional Cell Bladder Cancer (PDF)
High-risk superficial transitional cell bladder cancers are not muscle-invasive tumours but have a high predilection for the developing muscle invasion, metastasis and eventual mortality.

BJUI Mini Reviews 2005 October

Is Intravesical Chemotherapy For Superficial Bladder Cancer Still Justified? (PDF)
The use of intravesical chemotherapy in the management of superficial bladder cancer has been controversial in recent years.

BJUI Mini Reviews 2005 October

Molecular Staging of Bladder Cancer (PDF)
Cancer of the urinary bladder is a major epidemiological problem that continues to grow each year.

BJUI Mini Reviews 2005 July

The Role of Photodynamic Diagnosis in the Contemporary Management of Superficial Bladder Cancer (PDF)
Photodynamic diagnosis (PDD) for bladder tumours was reported as long as 40 years ago [1], but the modern era was heralded with the first clinical report of the use of 5-aminolaevulinic acid (5-ALA) as a photosensitizing agent [2].

BJUI Mini Reviews 2005 July

Genitourinary Medicine and Surgery in Prisons During the Period of Reform (PDF)
Prison reform in England began in the 1770s; before that prisoners could obtain medical attention at their own expense or, if they were lucky, funded by the authorities: ‘In 1674, a Dr Hodges was paid 10 pounds: "to inform himself of the gravity of the distemper in Wood Street compter (an archaic term for a prison)", and approval was granted for settlement of an apothecary’s bill for certain medicines used in treating the disease’.

BJUI Mini Reviews 2005 June

Molecular Prognostic Factors in Bladder Cancer (PDF)
Cancer cells are distinguished from normal cells by several hallmarks, including evasion of apoptosis, self-sufficiency in growth signalling, insensitivity to antigrowth signals, sustained angiogenesis, limitless replicative potential, propensity towards tissue invasion and metastasis [1].

BJUI Mini Reviews 2005 April

Molecular Pathways in Bladder Cancer: Part 1 (PDF)
Bladder cancer is the fifth most common malignancy in England and Wales, with 12 500 new cases and 5000 deaths per year [1]; worldwide, an estimated 336 000 new cases occur each year and its incidence is increasing [1,2].

BJUI Mini Reviews 2005 March

Molecular Pathways in Bladder Cancer: Part 2 (PDF)
Bladder cancer is the fifth most common malignancy in England and Wales, and is the second most common genitourinary tumour.

BJUI Mini Reviews 2005 March

Non-transitional Cell Bladder Carcinomas (PDF)
Of malignant bladder tumours, 90-95% are TCC (urothelial) and the remaining 5-10% are composed of mesenchymal and/or epithelial tumours of other histological types.

BJUI Mini Reviews 2005 March

The Role of the Nonsurgical Oncologist in the Management of Advanced Transitional Cell Cancer. Part I: Locally Advanced Disease (PDF)
TCC may arise at any site in the urinary tract, and when advanced or metastatic can be regarded by the nonsurgical oncologist as a single tumour type.

BJUI Mini Reviews 2004 November

The Role of the Nonsurgical Oncologist in the Management of Advanced Transitional Cell Cancer. Part II: Metastatic Disease (PDF)
The initial treatment of choice for locally advanced (T4b) or metastatic TCC of the bladder, or metastatic TCC arising at any other site, will be chemotherapy for the great majority of patients.

BJUI Mini Reviews 2004 November

Three-Dimensional Imaging in Urology (PDF)
Bestowed with binocular vision, humans can appreciate the world around them in three dimensions.

BJUI Mini Reviews 2004 October

Please log-in or register in order to submit comments.

Powered by AkoComment!